** British drugmaker's U.S.-listed shares up 2.5 pctat $45.35 premarket
** Company reports better-than-expected Q4 earnings,helped by cost cuts
** GSK reports lower-than-expected Q4 revenue, hurt by weaksales of lung drug Advair
** Up to Tuesday's close, U.S.-listed stock had fallen about13 pct in past 12 months